

RPG LIFE SCIENCES LIMITED

Regd. Office: RPG House, 463, Dr. Annie Besant Road, Worli, Mumbai 400 030.

CIN: L24232MH2007PLC169354;

Tel: +91-22-24981650; Fax: +91-22-24970127

E-mail: info@rpglifesciences.com; Web: www.rpglifesciences.com



PART I
STATEMENT OF STANDALONE AUDITED RESULTS FOR THE YEAR ENDED 31st MARCH, 2014 (Rs. in lakhs)

PARTICULARS	3 months ended			Year ended	
	31.3.2014	31.12.2013	31.3.2013	31.3.2014	31.3.2013
	Unaudited			Audited	
1. Income from Operations					
(a) Net Sales/Income from Operations (Net of Excise Duty)	5,114	5,479	5,634	22,938	21,621
(b) Other Operating Income	160	201	231	595	543
Total Income from Operations (Net)	5,274	5,680	5,865	23,533	22,164
2. Expenses					
(a) Cost of Materials Consumed	1,342	1,514	1,212	6,581	5,479
(b) Purchases of Stock-in-Trade	370	507	425	1,943	1,880
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	128	(85)	442	(849)	285
(d) Employee Benefits Expense	1,496	1,510	1,351	6,218	5,520
(e) Depreciation and Amortisation Expense	273	271	253	1,061	987
(f) Provision for Doubtful Debts and Advances (Net) [Refer Note 5]	-	681	27	689	34
(g) Other Expenses	1,748	1,841	1,662	7,805	7,359
Total Expenses	5,329	6,239	5,372	23,448	21,544
3. (Loss)/Profit from Operations before Other Income, Finance Costs and Exceptional Items	(55)	(559)	493	85	620
4. Other Income	40	49	66	258	178
5. (Loss)/Profit from Ordinary Activities before Finance Costs and Exceptional Items	(15)	(510)	559	343	798
6. Finance Costs	39	34	206	260	744
7. (Loss)/Profit from Ordinary Activities after Finance Costs but before Exceptional Items	(54)	(544)	353	83	54
8. Exceptional Items	(12)	-	-	6,414	-
9. (Loss)/Profit from Ordinary Activities before Tax	(66)	(544)	353	6,497	54
10. Tax (Credit)/Expense (including Deferred Tax)	(15)	(242)	(387)	1,157	(387)
11. Net (Loss)/Profit for the period	(51)	(302)	740	5,340	441
12. Paid-up Equity Share Capital (Face Value Rs. 8 each)	1,323	1,323	1,323	1,323	1,323
13. Reserves excluding Revaluation Reserves (as per last audited Balance Sheet)				11,253	6,300
14. (Loss)/Earnings per Share (of Rs. 8 each) (not annualised):					
(a) Basic	(0.31)	(1.83)	4.48	32.29	2.67
(b) Diluted	(0.31)	(1.83)	4.48	32.29	2.67

PART II

Select Information for the Quarter and Year ended 31st March, 2014

PARTICULARS	3 months ended			Year ended	
	31.3.2014	31.12.2013	31.3.2013	31.3.2014	31.3.2013
	Unaudited			Audited	
A PARTICULARS OF SHAREHOLDING					
1. Public Shareholding					
- Number of Shares	6,380,451	7,196,344	7,196,344	6,380,451	7,196,344
- Percentage of Shareholding	38.59	43.52	43.52	38.59	43.52
2. Promoters and Promoter Group Shareholding					
(a) Pledged/Encumbered					
- Number of Shares	-	-	-	-	-
- Percentage of Shares (as a % of the total shareholding of Promoter and Promoter Group)	-	-	-	-	-
- Percentage of Shares (as a % of the total Share Capital of the company)	-	-	-	-	-
(b) Non-Encumbered					
- Number of Shares	10,154,790	9,338,897	9,338,897	10,154,790	9,338,897
- Percentage of Shares (as a % of the total shareholding of Promoter and Promoter Group)	100.00	100.00	100.00	100.00	100.00
- Percentage of Shares (as a % of the total Share Capital of the company)	61.41	56.48	56.48	61.41	56.48

PARTICULARS	Year ended 31.03.2014
B INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	-
Received during the quarter	7
Disposed of during the quarter	7
Remaining unsolved during the quarter	-

Notes :

1. Standalone Statement of Assets and Liabilities

(Rs. in lakhs)

PARTICULARS	As at	
	31.3.2014	31.3.2013
A EQUITY AND LIABILITIES		
1. Shareholders' Funds		
(a) Share Capital	1,323	1,323
(b) Reserves and Surplus	11,253	6,300
Sub-total - Shareholders' Funds	12,576	7,623
2. Non-Current Liabilities		
(a) Long-term Borrowings	36	1,052
(b) Deferred Tax Liabilities (Net)	170	294
(c) Other Long-term Liabilities	306	315
(d) Long-term Provisions	142	125
Sub-total - Non-Current Liabilities	654	1,786
3. Current Liabilities		
(a) Short-term Borrowings	1,368	3,709
(b) Trade Payables	3,702	4,743
(c) Other Current Liabilities	519	2,401
(d) Short-term Provisions	788	314
Sub-total - Current Liabilities	6,377	11,167
TOTAL - EQUITY AND LIABILITIES	19,607	20,576
B ASSETS		
1. Non-Current Assets		
(a) Fixed Assets	10,689	10,418
(b) Long-term Loans and Advances	516	227
(c) Other Non-Current Assets	-	-
Sub-total - Non-Current Assets	11,205	10,645
2. Current Assets		
(a) Inventories	3,777	2,937
(b) Trade Receivables	3,634	4,929
(c) Cash and Bank Balances	70	78
(d) Short-term Loans and Advances	921	1,146
(e) Other Current Assets	-	841
Sub-total - Current Assets	8,402	9,931
TOTAL - ASSETS	19,607	20,576

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 30th April, 2014.
- The figures for the quarter ended 31st March, 2014 are the balancing figures between the audited financial results for the year ended 31st March, 2014 and the published unaudited financial results for the nine months ended 31st December, 2013.
- The Company is exclusively engaged in the pharmaceuticals segment.
- Provision for Doubtful Debts and Advances (Net) for the year ended 31st March, 2014 includes an amount of Rs. 674 lakhs towards receivable from certain parties to whom pharmaceutical goods were supplied as per contracts and for which these parties have reneged on the contractual payment terms. The Company has initiated legal action against these parties. Without prejudice to the position that Rs. 674 lakhs is recoverable, the Company has made provision for the same.
- Exceptional Items for the year ended 31st March, 2014 comprise of profit of Rs. 6,172 lakhs on such sale of a portion of leasehold land and building thereon and the Company's share of interest income of Rs. 242 lakhs earned on the sale consideration deposited by the buyer in an escrow account, jointly held in the name of the Company and the buyer, till the execution of the sale deed. The amount of sale consideration and the Company's share of interest income lying in the escrow account has been transferred to the Company on the date of execution of the sale deed.
- The Board of Directors of the Company has recommended a normal dividend of Rs.1.20 per share of Rs. 8 each (15 %) and a special dividend of Rs. 0.80 per share of Rs. 8 each (10%) on account of extraordinary income aggregating to total dividend of Rs. 2.00 per share of Rs. 8 each (25 %) for the year ended 31st March, 2014.
- Figures for the prior periods have been regrouped/reclassified where necessary.

For **RPGLife Sciences Limited**

Ajit Singh Chouhan
Managing Director

Mumbai, 30th April, 2014

